Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although advances are being made towards earlier detection and the development of impactful targeted therapies and immunotherapies, the 5-year survival of patients with advanced disease is still below 20%. Ef...
Main Authors: | Robert E. Hynds, Kristopher K. Frese, David R. Pearce, Eva Grönroos, Caroline Dive, Charles Swanton |
---|---|
Format: | Article |
Language: | English |
Published: |
The Royal Society
2021-01-01
|
Series: | Open Biology |
Subjects: | |
Online Access: | https://royalsocietypublishing.org/doi/pdf/10.1098/rsob.200247 |
Similar Items
-
Patient-Derived Organoids of Cholangiocarcinoma
by: Christopher Fabian Maier, et al.
Published: (2021-08-01) -
Cancer models in preclinical research: A chronicle review of advancement in effective cancer research
by: Humna Sajjad, et al.
Published: (2021-06-01) -
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
by: Thao N. D. Pham, et al.
Published: (2021-01-01) -
Novel organoid model in drug screening: Past, present, and future
by: Xialin Nie, et al.
Published: (2021-06-01) -
Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells
by: Takeshi Namekawa, et al.
Published: (2019-01-01)